Product Name: HIF1 alpha
Product Number: AB-NN267-1
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Hypoxia-inducible factor 1-alpha
Target Alias: ARNT interacting protein; HIF1A; MOP1; PASD8
Product Type Specific: Heat shock/stress protein pan-specific antibody
Antibody Code: NN267-1
Antibody Target Type: Pan-specific
Protein UniProt: Q16665
Protein SigNET: Q16665
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG1
Antibody Immunogen Source: Recombinant fragment corresponding to amino acids 329-530
Target Alias: ARNT interacting protein; HIF1A; MOP1; PASD8
Product Type Specific: Heat shock/stress protein pan-specific antibody
Antibody Code: NN267-1
Antibody Target Type: Pan-specific
Protein UniProt: Q16665
Protein SigNET: Q16665
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG1
Antibody Immunogen Source: Recombinant fragment corresponding to amino acids 329-530
Production Method: Protein G purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH7.4, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | ELISA
Antibody Dilution Recommended: WB (1:1000), IHC (1:8000), ICC/IF (1:50); optimal dilutions for assays should be determined by the user.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH7.4, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | ELISA
Antibody Dilution Recommended: WB (1:1000), IHC (1:8000), ICC/IF (1:50); optimal dilutions for assays should be determined by the user.
Antibody Potency: Detects a ~116 kDa protein in cell and tissue lysates by Western blotting. Specific for HIF1Alpha.
Antibody Species Reactivity: Human | Mouse | Rat | Bovine
Antibody Positive Control: 1 µg/ml of SMC-184 was sufficient for detection of HIF1α in 20 µg of CoCl2-induced Hela cell lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Very high
Antibody Species Reactivity: Human | Mouse | Rat | Bovine
Antibody Positive Control: 1 µg/ml of SMC-184 was sufficient for detection of HIF1α in 20 µg of CoCl2-induced Hela cell lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Very high
Scientific Background: Hypoxia-inducible factor 1 (HIF1) is a heterodimeric transcription factor that plays a critical role in the cellular response of hypoxia (1). The HIF1 complex consists of two subunits, HIF1-Alpha and HIF1-Beta, which are basic helix-loop-helix proteins of the PAS family (2). HIF1 regulates the transcription of a broad range of genes that facilitate responses to the hypoxic environment, including genes regulating angiogenesis, erythropoiesis, cell cycle, metabolism and apoptosis. The widely expressed HIF-1α is typically degraded rapidly in normoxic cells by the ubiquitin/proteasomal pathway. Under normoxic conditions, HIF-1α is proline hydroxylated leading to a conformational change that promotes binding to the von Hippel Lindau protein (VLH) E3 ligase complex; ubiquitination and proteasomal degradation follows (3, 4). Both hypoxic conditions and chemical hydroxylase inhibitors (such as desferrioxamine and cobalt) inhibit HIF-1α degradation and lead to its stabilization. In addition, HIF-1α can be induced in an oxygen-independent manner by various cytokines through the PI3K-AKT-mTOR pathway (5-7).
References
[1] Sharp F.R. and Bernaudin M. (2004) Nat Rev Neurosci 5: 437-48.
[2] Wang G.L. et al. (1995) Proc Natl Acad Sci U S A 92: 5510-4.
[3] Jaakkola P. et al. (2001) Science 292: 468-72.
[4] Maxwell P.H. et al. (1999) Nature 399: 271-5.
[5] Fukuda R. et al. (2002) J Biol Chem 277: 38205-11.
[6] Jiang B.H. et al. (2001) Cell Growth Differ 12: 363-9.
[7] Laughner E. et al. (2001) Mol Cell Biol 21: 3995-4004.
[1] Sharp F.R. and Bernaudin M. (2004) Nat Rev Neurosci 5: 437-48.
[2] Wang G.L. et al. (1995) Proc Natl Acad Sci U S A 92: 5510-4.
[3] Jaakkola P. et al. (2001) Science 292: 468-72.
[4] Maxwell P.H. et al. (1999) Nature 399: 271-5.
[5] Fukuda R. et al. (2002) J Biol Chem 277: 38205-11.
[6] Jiang B.H. et al. (2001) Cell Growth Differ 12: 363-9.
[7] Laughner E. et al. (2001) Mol Cell Biol 21: 3995-4004.
© Kinexus Bioinformatics Corporation 2017